AstraZeneca Plc (NASDAQ:AZN) on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when combined with lenvatinib and transarterial chemoembolization (TACE), significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (a type of liver cancer) eligible for embolization.
The data, being presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, also showed an encouraging trend toward improved overall survival.
• AstraZeneca stock is under selling pressure. What’s pulling AZN shares down?
EMERALD-3 Meets Primary Endpoint With Significant PFS Improvement
The EMERALD-3 study evaluated AstraZeneca's Imfinzi (durvalumab) and Imjudo (tremelimumab) as part of the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen, administered with or without lenvatinib before TACE and continued alongside TACE treatment.
